全覆膜药物洗脱支架与药物涂层球囊治疗股腘动脉原发病变的三年TASC II分层结果
该回顾性单中心研究纳入419例患者(507条肢体)的原发股腘动脉病变,按TASC II分层比较全覆膜药物洗脱支架(DES)与药物涂层球囊(DCB)的3年疗效。在TASC II A/B病变中,DES与DCB的3年一期通畅率相当(80.0% vs 76.9%,p=0.432);在TASC II C/D病变中,DES的3年一期通畅率(85.1% vs 50.3%,p<0.001)和免于靶病变血运重建率(90.2% vs 66.7%,p=0.008)均优于DCB。结论提示应根据病变复杂度选择器械。
要点
- TASC II A/B股腘动脉原发病变中,DES与DCB的3年一期通畅率相当。
- TASC II C/D病变中,DES的3年一期通畅率和免于TLR率均优于DCB。
- DCB组中C/D病变的3年一期通畅率低于A/B病变,而DES组各分层结果一致。
核心结论
- 在TASC II A/B股腘动脉原发病变中,全覆膜DCB与DES的3年疗效相当,支持在合适病例中采用无支架策略。
- 在TASC II C/D病变中,DES提供了更优的长期通畅率和更低的再干预率,凸显基于病变复杂度选择器械的重要性。
研究设计与样本
- 回顾性单中心研究,纳入2019至2021年治疗的419例患者(507条肢体)的原发股腘动脉病变。
- 肢体按TASC II分层为A/B组(186条肢体)和C/D组(321条肢体),分别接受DES(107条肢体)或DCB(400条肢体)治疗。
- 主要终点为3年一期通畅率,定义为免于靶病变血运重建(TLR)或双功超声检测的再狭窄(收缩期峰值流速比≥2.5)。
主要发现
- TASC II A/B病变中,DES与DCB的3年一期通畅率(80.0% vs 76.9%,p=0.432)、免于TLR率(84.2% vs 88.0%,p=0.959)和免于截肢生存率(AFS)(74.3% vs 78.3%,p=0.834)均无显著差异。
- TASC II C/D病变中,DES的3年一期通畅率(85.1% vs 50.3%,p<0.001)和免于TLR率(90.2% vs 66.7%,p=0.008)均高于DCB,而AFS无显著差异(90.2% vs 66.7%,p=0.074)。
- DCB组中C/D病变的3年一期通畅率低于A/B病变(50.3% vs 76.9%,p<0.001),而DES组各分层间无差异(85.1% vs 80.0%,p=0.828)。
- 3年再闭塞率在A/B组中DES与DCB相似(20% vs 15%,p=0.544),在C/D组中DES更高(60% vs 29%,p=0.044)。
- 多变量分析显示,膝下流出道≤1(HR=1.96)和TASC II D分类(HR=2.57)是DCB治疗的C/D病变再狭窄的独立预测因素;缺血性伤口(HR=6.61)和广泛偏心性钙化(HR=14.3)预测DES治疗的A/B病变再狭窄。
临床怎么用
- 对于TASC II A/B股腘动脉原发病变,可考虑优先使用DCB,在合适病例中避免支架植入。
- 对于TASC II C/D复杂病变,DES可能提供更优的长期通畅率,应优先考虑DES。
- 器械选择应基于TASC II病变复杂度分层,以实现个体化治疗。
局限性
- 本研究为回顾性单中心设计,可能存在选择偏倚。
- DES与DCB两组肢体数量不平衡(107 vs 400),可能影响结果解释。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Paclitaxel-based devices improve femoropopliteal outcomes; however, the optimal strategy for de novo lesions by lesion complexity remains uncertain. This study compared long-term outcomes of full-coverage drug-eluting stent (DES) implantation and drug-coated balloon (DCB) angioplasty stratified by the Trans-Atlantic Inter-Society Consensus II (TASC II) classification. METHODS: This retrospective, single-center study included 419 patients (507 limbs) with de novo femoropopliteal lesions treated between 2019 and 2021. Limbs were stratified into TASC II A/B (186 limbs) and C/D (321 limbs) groups and treated with DES (107 limbs) or DCB (400 limbs). The primary endpoint was 3-year primary patency, defined as freedom from target lesion revascularization (TLR) or duplex ultrasound-detected restenosis (peak systolic velocity ratio ≥2.5). Secondary endpoints included 3-year freedom from TLR and amputation-free survival (AFS). RESULTS: In TASC II A/B lesions, 3-year primary patency was comparable between DES and DCB (80.0% vs 76.9%, p=0.432), as were freedom from TLR (84.2% vs. 88.0%, p=0.959) and AFS (74.3% vs 78.3%, p=0.834). In TASC II C/D lesions, DES achieved higher 3-year primary patency (85.1% vs 50.3%, p<0.001) and freedom from TLR (90.2% vs 66.7%, p=0.008) than DCB, while AFS did not differ significantly (90.2% vs 66.7%, p=0.074). Within the DCB cohort, 3-year primary patency was lower for C/D than A/B lesions (50.3% vs 76.9%, p<0.001), whereas DES outcomes were consistent across strata (85.1% vs 80.0%, p=0.828). The AFS was comparable between the 2 strategies across both TASC II strata. Regarding restenosis patterns, 3-year reocclusion rates were similar in A/B (DES 20% vs DCB 15%, p=0.544), whereas they were higher with DES in C/D (60% vs 29%, p=0.044). On multivariable analysis, below-the-knee runoff ≤1 (hazard ratio [HR]=1.96) and TASC II D classification (HR=2.57) were independent predictors of restenosis in DCB-treated C/D lesions, whereas ischemic wounds (HR=6.61) and extensive eccentric calcification (HR=14.3) predicted restenosis in DES-treated A/B lesions. CONCLUSION: Full-coverage DCB and DES yielded favorable outcomes in TASC II A/B lesions, supporting a stentless strategy in selected cases. For TASC II C/D lesions, DES provided superior long-term patency and lower reintervention rates, highlighting the importance of lesion complexity-based device selection.Clinical ImpactThis study demonstrates that lesion complexity, as defined by the TASC II classification, is a decisive factor in device selection for femoropopliteal interventions. In de novo TASC II A/B lesions, full-coverage drug-coated balloon angioplasty and drug-eluting stent implantation achieved comparable 3-year outcomes, supporting a stentless approach in suitable cases. In contrast, the drug-eluting stent strategy provided superior long-term patency in complex TASC II C/D lesions, emphasizing the value of full-lesion coverage and optimized lumen expansion. These findings offer lesion-specific guidance that may refine treatment algorithms, improve durability of revascularization, and support individualized therapy in peripheral artery disease.
引用
- Haraguchi T, Tsujimoto M, Kasai Y, et al. Full-Coverage Drug-Eluting Stent Vs Drug-Coated Balloon in De Novo Femoropopliteal Lesions: Three-Year TASC II-Stratified Outcomes. J Endovasc Ther. 2026. PMID: 41709598. doi:10.1177/15266028261420088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。